The purpose of the present invention is to provide a novel hair growth promoter. The features of the present invention for solving the problem are as follows. 1. A hair growth promoter containing an extract of yellow strawberry guava fruit as an active ingredient. 2. An agent for promoting vascular endothelial cell growth factor production, containing an extract of yellow strawberry guava fruit as an active ingredient. 3. A food or drink composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 4. A pharmaceutical composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 5. A hair cosmetic composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 6. A topical skin preparation composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 7. A hair growth promoter for use in oral administration, containing an aqueous ethanol extract of yellow strawberry guava fruit as an active ingredient.
A 5α-reductase inhibitor contains saw palmetto extract and seaberry extract as an active ingredient in a synergistic compounding ratio, wherein the compounding ratio by weight of the saw palmetto extract and the seaberry extract is 3:1˜2. The 5α-reductase inhibitor containing the saw palmetto extract and seaberry extract or just the seaberry extract as a 5α-reductase inhibitor can be administered to the human body in order to inhibit 5α-reductase. The 5α-reductase inhibitor is useful as a prostate enlargement inhibitor, an androgenic alopecia inhibitor, and an acne prevention and amelioration agent. The 5α-reductase inhibitor can be part of a food or drink composition or a cosmetic composition.
Provided is a new immunostimulant. The features of the present invention for solving the problem are as follows. 1. An agent for promoting production of IL-6 in dendritic cells, the agent comprising, as an active ingredient, at least one selected from GlcCer[d18:2(4E,8Z)/18:0], GlcCer[d18:2(4E,8Z)/26:0], GlcCer[t18:1(8Z)/20:0], and Cer[t18:0/22:0]. 2. The agent for promoting production of IL-6 according to 1. described above, the agent being characterized in that the production of IL-6 is carried out through binding to TLR2 and/or TLR4. 3. An agent for causing proliferation of helper T-cells by dendritic cells, the agent comprising, as an active ingredient, at least one selected from GlcCer[d18:2(4E,8Z)/18:0] and GlcCer[d18:2(4E,8Z)/26:0]. 4. An activator for presenting an antigen to dendritic cells, the activator comprising, as an active ingredient, GlcCer[d18:2(4E,8Z)/18:0]. 5. An immunostimulant comprising, as an active ingredient, at least one selected from GlcCer[d18:2(4E,8Z)/18:0], GlcCer[d18:2(4E,8Z)/26:0], GlcCer[t18:1(8Z)/20:0], and Cer[t18:0/22:0].
The present invention addresses the problem of providing: a novel compound; and a use of the compound. The features of the present invention for solving the problem are as follows. 1. A compound represented by chemical formula (1). 2. A compound represented by chemical formula (2). 3. A transepidermal water loss reducing agent containing the compound mentioned in 1 or 2 as an active ingredient. 4. A moisturizing agent containing the compound mentioned in 1 or 2 as an active ingredient. 5. An agent for promoting the production of interleukin-6 in dendritic cells, which contains the compound mentioned in 1 or 2 as an active ingredient. 6. An immunostimulant containing the compound mentioned in 1 or 2 as an active ingredient. 7. A method for producing the compound mentioned in 1 or 2, the method being characterized by including a step for isolating the compound from an extract from rice bran.
C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
A23G 3/36 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition
A23G 4/06 - Chewing gum characterised by the composition
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Camellia sinensis; variety name: TRFK306) containing 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-β-D-glucose (GHG). Then, an effective amount of the purple tea extract is administered to a body of a human being engaged in intensive exercise to reduce muscle damage associated with the intensive exercise.
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
6.
Method of administering seaberry and saw palmetto extracts to inhibit 5α-reductase activity
A 5α-reductase inhibitor contains saw palmetto extract and seaberry extract as an active ingredient in a synergistic compounding ratio, wherein the compounding ratio by weight of the saw palmetto extract and the seaberry extract is 3:1˜2. The 5α-reductase inhibitor containing the saw palmetto extract and seaberry extract or just the seaberry extract as a 5α-reductase inhibitor can be administered to the human body in order to inhibit 5α-reductase. The 5α-reductase inhibitor is useful as a prostate enlargement inhibitor, an androgenic alopecia inhibitor, and an acne prevention and amelioration agent. The 5α-reductase inhibitor can be part of a food or drink composition or a cosmetic composition.
Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
[Problem] To provide a 5α-reductase inhibitor which contains a novel component as an active ingredient. [Solution] The features of the present invention are as follows. 1. A 5α-reductase inhibitor containing a sea berry extract as an active ingredient. 2. A 5α-reductase inhibitor containing, as active ingredients, a sea berry extract and a saw palmetto extract at such a blend ratio that a synergic effect can be exerted. 3. The 5α-reductase inhibitor according to the above-mentioned item 2, characterized in that the weight-based mixing ratio between the saw palmetto extract and the sea berry extract (i.e., (saw palmetto extract):(sea berry extract)) is (3 to 1):(1 to 2). 4. A prostatic hyperplasia-preventing agent containing a 5α-reductase inhibitor as recited in any one of the above-mentioned items 1 to 3 as an active ingredient. 5. An androgenic alopecia-preventing agent containing a 5α-reductase inhibitor as recited in any one of the above-mentioned items 1 to 3 as an active ingredient. 6. An acne-preventing/ameliorating agent containing a 5α-reductase inhibitor as recited in any one of the above-mentioned items 1 to 3 as an active ingredient.
A23G 3/48 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition containing plants or parts thereof, e.g. fruits, seeds, extracts
A23G 4/06 - Chewing gum characterised by the composition
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary and nutritional supplements; dietary and nutritional
supplements containing glycosphingolipid of rice origin or
containing ceramide derived from glycosphingolipid of rice
origin, in the form of powder, granule, liquid, capsule
(including hard capsule, soft capsule, microcapsule or the
like) and tablet; dietary and nutritional supplements with a
cosmetic effect.
[Problem] The purpose of the present invention is to provide a novel AMPK activator. [Solution] The technical features of the present invention for solving the above problem are as follows. 1. An AMPK activator having 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-b-D-glucose ("GHG" hereinafter) as an active ingredient. 2. An AMPK activator comprising a GHG-containing composition that includes GHG as an active ingredient. 3. An AMPK activator comprising a GHG-containing composition derived from Kenyan purple tea (scientific name: Camellia sinensis, variety name TRFK306).
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
purple tea extract for use in the manufacture of foods, beverages and dietary supplements extract of purple tea sold as a component ingredient of dietary supplements
[Problem] The purpose of the present invention is to provide a novel ECM cycle normalizer. [Solution] The technical features of the present invention for solving the above problem are as follows. 1. A normalizer of the collagen production and uptake cycle in skin fibroblasts, the normalizer having lycoperoside A as an active ingredient. 2. A normalizer of the elastin production and uptake cycle in skin fibroblasts, the normalizer having lycoperoside A as an active ingredient. 3. A normalizer of the ECM cycle in skin fibroblasts, the normalizer having lycoperoside A as an active ingredient.
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
[Problem] The purpose of the present invention is to provide a novel body odor component reducer. [Solution] The technical feature of the present invention for solving the above problem is described below. 1. A body odor component reducer having as an active ingredient a plant extract containing thymoquinone. 2. The body odor component reducer according to 1. above, wherein the plant extract is black cumin extract. 3. A body odor component reducer having thymoquinone as an active ingredient. 4. The body odor component reducer according to any one of 1. through 3. above, wherein the body odor component is at least one species selected from butyric acid and isovaleric acid. 5. A body odor component reducer having black cumin extract as an active ingredient. 6. A body odor component reducer characterized in that the body odor component is at least one species selected from butyric acid, isovaleric acid, diacetyl, and ammonia.
[Problem] To provide: an estrogen activity modulator which contains, as an active ingredient, a novel component that can exhibit an estrogen-like activity in the absence of estrogen and can act antagonistically in the presence of estrogen; and an agent for ameliorating unidentified complaints associated with a menstrual cycle, which is produced using the estrogen activity modulator. [Solution] The characteristic features of the present invention that can solve the problem reside in the followings. (1) An estrogen activity modulator which can exhibit an estrogen-like activity in the absence of estrogen and can exhibit an estrogen-inhibiting activity in the presence of estrogen, and which contains a pterocarpan compound as an active ingredient. (2) An estrogen activity modulator which can exhibit an estrogen-like activity in the absence of estrogen and can exhibit an estrogen-inhibiting activity in the presence of estrogen, and which contains, as an active ingredient, an Aguaje extract containing 8-hydroxyhomopterocarpan and lespeflorin G8. (3) An agent for ameliorating unidentified complaints associated with a menstrual cycle, which contains a pterocarpan compound as an active ingredient. (4) An agent for ameliorating unidentified complaints associated with a menstrual cycle, which contains, as an active ingredient, an Aguaje extract containing 8-hydroxyhomopterocarpan and lespeflorin G8.
A23L 33/11 - Plant sterols or derivatives thereof, e.g. phytosterols
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A23L 35/00 - Foods or foodstuffs not provided for in groups Preparation or treatment thereof
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 36/889 - Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
Provided are a novel use of 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-β-D-glucose (hereinafter abbreviated as "GHG") which is contained in a large amount in purple tea produced in Kenya (scientific name: Camellia sinensis, variety name: TRFK306); and a novel circadian rhythm regulator which is widely usable as medicines, beverages, foods and cosmetics. The circadian rhythm regulator according to the present invention is characterized by comprising GHG as an active ingredient having an effect of promoting the expression of Bmal1 gene. Also, the circadian rhythm regulator according to the present invention is characterized by comprising a GHG-containing extract derived from the purple tea produced in Kenya as an active ingredient having an effect of promoting the expression of Bmal1 gene.
This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
The present invention addresses the problem of providing a novel muscle energy metabolism activator, etc. and a composition that can be taken as a drug or a food. To solve the above problem, the technical features of the present invention are as follows. (1) A glucose transporter (GLUT4) gene expression promoter comprising as an active ingredient at least one member selected from among 5-hydroxy-3,7-dimethoxyflavone, techtochrysin, 3,7,4'-trimethyl kaempferol, retusine, pentamethyl quercetin, trimethyl apigenin, tetramethyl kaempferol and 5,7-dimethoxyflavone. (2) A glucose transporter (GLUT4) gene expression promoter comprising as an active ingredient at least one member selected from techtochrysin and 5,7-dimethoxyflavone. (3) A glucose transporter (GLUT4) gene expression promoter in muscle cells, said promoter comprising at least one compound represented by chemical formula (1) [wherein R1 and R2 represent each hydrogen or an alkyl group having 1-3 carbon atoms].
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61P 43/00 - Drugs for specific purposes, not provided for in groups
19.
Methods for inhibiting advanced glycation end product production, inhibiting fibroblast apoptosis, and/or promoting human fibroblast-collagen grating formulation using cherry blossom and cherry leaf extract
Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside.
A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A23G 3/36 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition
A23G 4/06 - Chewing gum characterised by the composition
A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Purple tea extracts containing 1, 2-di-O-Galloyl-4,6-O-hexahydroxydiphenoyl-beta-D-glucose used as an ingredient in the manufacture of [ beverages, ] nutritional supplements [, and foods ]
The objective of the present invention is to provide: a 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-b-D-glucose (hereinafter abbreviated as "GHG") containing composition that is a composition derived from a natural product and that contains a high concentration of GHG. The GHG-containing composition is characterized by being obtained from purple tea (scientific name: Camellia sinensis, cultivar name TRFK306) from Kenya, and having 3-10 mass% of GHG. The method for producing the GHG-containing composition is characterized by immersing the purple tea (scientific name: Camellia sinensis, cultivar name TRFK306) from Kenya in a polar solvent (including water), and then heating to reflux and extracting the GHG in the solvent.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
Provided is a prophylactic/therapeutic agent for dry eye, which comprises a novel component capable of preventing the deterioration of a tear fluid secretion ability and also capable of inhibiting the generation of active oxygen in tear gland tissues. The prophylactic/therapeutic agent for dry eye according to the present invention contains a maqui berry extract as an active ingredient. The prophylactic/therapeutic agent for dry eye according to the present invention may contain, as an active ingredient, a delphinidin glycoside that is extracted from maqui berry. The prophylactic/therapeutic agent for dry eye according to the present invention may contain at least one component selected from delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, desirably delphinidin-3,5-diglucoside, as an active ingredient.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diseases and conditions of the eye; dietary supplements for humans and animals; Plant extracts sold as a component ingredient of dietetic foods, namely, biscuits, cereal bars and cereal based snack foods and dietetic substances adapted for medical use; Plant extracts sold as a component ingredient food for babies; Plant extracts sold as a component ingredient of dietetic sugar substitutes for medical use
Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains an extract of cherry (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active ingredient. The AGE production inhibitor or the like contains, as an active ingredient, at least one compound that is selected from the group consisting of 1-O-(E)-caffeoyl-β-D-glucopyranoside, 1-O-(E)-coumaroyl-β-D-glucopyranoside, 1-O-(E)-cinnamoyl-β-D-glucopyranoside, kaempferol 3-O-β-D-glucopyranoside, quercetin 3-O-β-D-glucopyranoside, kaempferol 3-O-(6"-malonyl)-β-D-glucopyranoside, and quercetin 3-O-(6"-malonyl)-β-D-glucopyranoside.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/00 - Drugs for disorders of the nervous system
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
[PROBLEMS] To provide: a novel agent having an inhibitory activity on hyaluronidase; and an anti-aging agent for the skin, an anti-inflammatory agent and others each of which comprises the agent. [MEANS FOR SOLVING PROBLEMS] Disclosed is a hyaluronidase inhibitor comprising a phenylethanoid glucoside as an active ingredient. The phenylethanoid glucoside preferably comprises at least one of echinacoside and acteoside. Also disclosed is a hyaluronidase inhibitor comprising an extract of a plant belonging to the family Cistanche as an active ingredient. The extract of a plant belonging to the family Cistanche is preferably isan extract from a stem of a plant Cistanche tubulosa. Each of the hyaluronidase inhibitors can be used in a pharmaceutical product for a mammal including human, an external preparation for the skin, a food/beverage or a feed for a mammal as an active ingredient of an anti-aging agent for the skin or an anti-inflammatory agent.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
